Cefotaxime/sulbactam: clinical and pharmacological characteristics

Clinical Microbiology and Antimicrobial Chemotherapy. 2019; 21(3):212-216

Type
Review

Abstract

The recently approved cefotaxime/sulbactam, combination of third-generation cephalosporin (cefotaxime) and beta-lactamase inhibitor (sulbactam), can combat resistance mechanisms associated with the production of serine beta-lactamases, including some extended spectrum beta-lactamases. This paper reviews the use of this combination antibiotic in clinical practice based on the current data on antimicrobial resistance in pathogens causing lower respiratory tract infections and the results of completed clinical studies of its efficacy and safety.

Views
0 Abstract
0 PDF
0 Crossref citations
Shared